86
Participants
Start Date
May 13, 2020
Primary Completion Date
December 30, 2021
Study Completion Date
June 30, 2022
CYNK-001
CYNK-001 is an allogeneic off the shelf cell therapy enriched for CD56+/CD3- NK cells expanded from human placental CD34+ cells.
Scripps Health, San Diego
UC Irvine, Irvine
UC Davis Medical Center, Sacramento
Multicare Health System, Tacoma
Hackensack University Medical Center, Hackensack
Atlantic Health, Morristown
Atlantic Health, Summit
Collaborators (1)
Access to Advanced Health Institute (AAHI)
OTHER
Lung Biotechnology PBC
INDUSTRY
California Institute for Regenerative Medicine (CIRM)
OTHER
Celularity Incorporated
INDUSTRY